Literature DB >> 25336571

Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.

Omar Abdel-Rahman1, Angela Lamarca1, Juan W Valle2, Richard A Hubner3.   

Abstract

Sorafenib is the only systemic therapy to demonstrate a significant survival benefit over supportive care in robust randomised controlled trials for advanced hepatocellular carcinoma (HCC). In the context of an intense search for prognostic and predictive factors for response and efficacy of different systemic therapies (including sorafenib), a number of molecular targets have been identified, paving new avenues for potential therapeutic opportunities. Such molecular targets include somatostatin receptor (SSTR)-related alterations. In this review, we provide an overview of the various considerations relating to SSTRs as potentially novel prognostic and predictive biomarkers for HCC with special emphasis on the therapeutic potential of somatostatin analogues in HCC management.
© 2014 Society for Endocrinology.

Entities:  

Keywords:  hepatocellular carcinoma; lanreotide; octreotide; somatostatin analogues; somatostatin receptors

Mesh：

Substances：

Year:  2014        PMID： 25336571     DOI： 10.1530/ERC-14-0389

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN： 1351-0088            Impact factor:   5.678


  8 in total

1.  Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors.

Authors:  Zhi Rong Qian; Tingting Li; Monica Ter-Minassian; Juhong Yang; Jennifer A Chan; Lauren K Brais; Yohei Masugi; Arunthathi Thiaglingam; Nichole Brooks; Reiko Nishihara; Mireille Bonnemarie; Atsuhiro Masuda; Kentaro Inamura; Sun A Kim; Kosuke Mima; Yasutaka Sukawa; Ruoxu Dou; Xihong Lin; David C Christiani; Fabien Schmidlin; Charles S Fuchs; Umar Mahmood; Shuji Ogino; Matthew H Kulke
Journal:  Pancreas       Date:  2016-11       Impact factor: 3.327

Review 2.  Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.

Authors:  Jaleh Varshosaz; Maryam Farzan
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

3.  Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT.

Authors:  Gary A Ulaner; Lisa Bodei
Journal:  Clin Nucl Med       Date:  2019-04       Impact factor: 7.794

Review 4.  Systemic treatment for hepatocellular carcinoma: Still unmet expectations.

Authors:  Dimitrios N Samonakis; Elias A Kouroumalis
Journal:  World J Hepatol       Date:  2017-01-18

5.  Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome.

Authors:  Romain Appay; Emeline Tabouret; Mehdi Touat; Catherine Carpentier; Carole Colin; François Ducray; Ahmed Idbaih; Karima Mokhtari; Emmanuelle Uro-Coste; Caroline Dehais; Dominique Figarella-Branger
Journal:  Acta Neuropathol Commun       Date:  2018-09-07       Impact factor: 7.801

Review 6.  Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy.

Authors:  Romain Eychenne; Christelle Bouvry; Mickael Bourgeois; Pascal Loyer; Eric Benoist; Nicolas Lepareur
Journal:  Molecules       Date:  2020-09-02       Impact factor: 4.411

Review 7.  The role of neuropeptide somatostatin in the brain and its application in treating neurological disorders.

Authors:  You-Hyang Song; Jiwon Yoon; Seung-Hee Lee
Journal:  Exp Mol Med       Date:  2021-03-19       Impact factor: 8.718

Review 8.  Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy.

Authors:  Yuheng Hu; Zeng Ye; Fei Wang; Yi Qin; Xiaowu Xu; Xianjun Yu; Shunrong Ji
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-19       Impact factor: 5.555
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.